Vitamin D3, JAMA publication showing efficacy in MS.

In reviewing the JAMA article, we wanted to share a brief overview of the well-established health benefits of Vitamin D3 (cholecalciferol), a nutrient that plays a vital role in maintaining overall health and wellbeing.

 Vitamin D3 is essential for calcium and phosphorus homeostasis, supporting bone mineralisation and skeletal integrity (Holick, 2007). Inadequate levels have been associated with conditions such as osteoporosis, increased fracture risk, and muscle weakness, particularly in older adults. We know this.

Beyond bone health, and lesser known, Vitamin D3 has demonstrated immune-modulating properties, supporting both innate and adaptive immunity. Recent studies suggest that sufficient Vitamin D3 levels may reduce the risk of acute respiratory infections, including influenza and COVID-19, especially in individuals with existing deficiencies (Martineau et al., 2017; Grant et al., 2020).

There is also growing evidence linking adequate Vitamin D3 status with reduced incidence of chronic conditions such as cardiovascular disease, type 2 diabetes, and some autoimmune disorders (Pilz et al., 2019). Additionally, it contributes to mental well-being, with low levels associated with symptoms of depression and cognitive decline in some populations (Anglin et al., 2013).

Now, JAMA adds plausible potential in MS.

Whilst we can argue we get Vitamin D3 from the sun, the truth is we don't; D3 should be a staple that is part of a patient's daily supplementation regime.